The biologic basis for combined modality treatment of cancer

L. W. Brady, Arnold Markoe

Research output: Contribution to journalArticle

Abstract

Strategies relative to cancer should be aimed at optimization of local and regional treatment. Delineation of subsets of patients with high risk for recurrence would have a significant impact, upon which such adjunctive systems of therapeutic management should be evaluated. The initiation of adjuvant therapy studies has great potential for improving the control rate in cancer. In disseminated disease, or where the probability of dissemination is high, evaluation of any realistic potential combination of treatment for tumor control should be pursued. It is necessary to delineate optimal palliative therapy where tumor control is not possible, but also to test new drugs, immunotherapeutic tools and combination regimens in all such situations where the disseminated compartment of the disease is of high probability. Only under such circumstances will the most practical and important optimization of treatment programs be achieved. The development of the above basic attributes for each tumor type needs to be studied so that protocols can be developed with a clear understanding of the nature of the disease, condition to be studied, and the general therapeutic strategies to be followed. This type of disease orientation and study includes the essentials necessary to make appropriate decisions. These data include adequate diagnostic evaluation, adequate clinical and pathologic staging, pathology review, delineation of relapse and recurrence patterns, criteria for response delineation, standardized follow-up routine and adequate data retrieval and analysis techniques to maximize the acquisition of appropriate information necessary to change treatment programs in the appropriate manner. Through such mechanisms, new therapeutic regimens can be demonstrated, tried, and expeditiously implemented for the benefit of the cancer patient.

Original languageEnglish
Pages (from-to)5-18
Number of pages14
JournalCancer Clinical Trials
Volume2
Issue number1
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Recurrence
Information Storage and Retrieval
Palliative Care
Pathology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The biologic basis for combined modality treatment of cancer. / Brady, L. W.; Markoe, Arnold.

In: Cancer Clinical Trials, Vol. 2, No. 1, 01.12.1979, p. 5-18.

Research output: Contribution to journalArticle

@article{f39e15bfa4994f57b02bb3956318f8ba,
title = "The biologic basis for combined modality treatment of cancer",
abstract = "Strategies relative to cancer should be aimed at optimization of local and regional treatment. Delineation of subsets of patients with high risk for recurrence would have a significant impact, upon which such adjunctive systems of therapeutic management should be evaluated. The initiation of adjuvant therapy studies has great potential for improving the control rate in cancer. In disseminated disease, or where the probability of dissemination is high, evaluation of any realistic potential combination of treatment for tumor control should be pursued. It is necessary to delineate optimal palliative therapy where tumor control is not possible, but also to test new drugs, immunotherapeutic tools and combination regimens in all such situations where the disseminated compartment of the disease is of high probability. Only under such circumstances will the most practical and important optimization of treatment programs be achieved. The development of the above basic attributes for each tumor type needs to be studied so that protocols can be developed with a clear understanding of the nature of the disease, condition to be studied, and the general therapeutic strategies to be followed. This type of disease orientation and study includes the essentials necessary to make appropriate decisions. These data include adequate diagnostic evaluation, adequate clinical and pathologic staging, pathology review, delineation of relapse and recurrence patterns, criteria for response delineation, standardized follow-up routine and adequate data retrieval and analysis techniques to maximize the acquisition of appropriate information necessary to change treatment programs in the appropriate manner. Through such mechanisms, new therapeutic regimens can be demonstrated, tried, and expeditiously implemented for the benefit of the cancer patient.",
author = "Brady, {L. W.} and Arnold Markoe",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "5--18",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The biologic basis for combined modality treatment of cancer

AU - Brady, L. W.

AU - Markoe, Arnold

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Strategies relative to cancer should be aimed at optimization of local and regional treatment. Delineation of subsets of patients with high risk for recurrence would have a significant impact, upon which such adjunctive systems of therapeutic management should be evaluated. The initiation of adjuvant therapy studies has great potential for improving the control rate in cancer. In disseminated disease, or where the probability of dissemination is high, evaluation of any realistic potential combination of treatment for tumor control should be pursued. It is necessary to delineate optimal palliative therapy where tumor control is not possible, but also to test new drugs, immunotherapeutic tools and combination regimens in all such situations where the disseminated compartment of the disease is of high probability. Only under such circumstances will the most practical and important optimization of treatment programs be achieved. The development of the above basic attributes for each tumor type needs to be studied so that protocols can be developed with a clear understanding of the nature of the disease, condition to be studied, and the general therapeutic strategies to be followed. This type of disease orientation and study includes the essentials necessary to make appropriate decisions. These data include adequate diagnostic evaluation, adequate clinical and pathologic staging, pathology review, delineation of relapse and recurrence patterns, criteria for response delineation, standardized follow-up routine and adequate data retrieval and analysis techniques to maximize the acquisition of appropriate information necessary to change treatment programs in the appropriate manner. Through such mechanisms, new therapeutic regimens can be demonstrated, tried, and expeditiously implemented for the benefit of the cancer patient.

AB - Strategies relative to cancer should be aimed at optimization of local and regional treatment. Delineation of subsets of patients with high risk for recurrence would have a significant impact, upon which such adjunctive systems of therapeutic management should be evaluated. The initiation of adjuvant therapy studies has great potential for improving the control rate in cancer. In disseminated disease, or where the probability of dissemination is high, evaluation of any realistic potential combination of treatment for tumor control should be pursued. It is necessary to delineate optimal palliative therapy where tumor control is not possible, but also to test new drugs, immunotherapeutic tools and combination regimens in all such situations where the disseminated compartment of the disease is of high probability. Only under such circumstances will the most practical and important optimization of treatment programs be achieved. The development of the above basic attributes for each tumor type needs to be studied so that protocols can be developed with a clear understanding of the nature of the disease, condition to be studied, and the general therapeutic strategies to be followed. This type of disease orientation and study includes the essentials necessary to make appropriate decisions. These data include adequate diagnostic evaluation, adequate clinical and pathologic staging, pathology review, delineation of relapse and recurrence patterns, criteria for response delineation, standardized follow-up routine and adequate data retrieval and analysis techniques to maximize the acquisition of appropriate information necessary to change treatment programs in the appropriate manner. Through such mechanisms, new therapeutic regimens can be demonstrated, tried, and expeditiously implemented for the benefit of the cancer patient.

UR - http://www.scopus.com/inward/record.url?scp=0018739924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018739924&partnerID=8YFLogxK

M3 - Article

C2 - 93031

AN - SCOPUS:0018739924

VL - 2

SP - 5

EP - 18

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -